Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.

Claudia Wellbrock

doi:10.15252/emmm.201505431

Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.

Claudia Wellbrock

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	EMBO Molecular Medicine
Volume	7
Issue number	9
DOIs	https://doi.org/10.15252/emmm.201505431
Publication status	Published - Sept 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.15252/emmm.201505431

Cite this

@article{eac62dbd8cfb4b6cb01c3ba373240426,

title = "Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.",

author = "Claudia Wellbrock",

year = "2015",

month = sep,

doi = "10.15252/emmm.201505431",

language = "English",

volume = "7",

journal = "EMBO Molecular Medicine ",

issn = "1757-4684",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.

AU - Wellbrock, Claudia

PY - 2015/9

Y1 - 2015/9

U2 - 10.15252/emmm.201505431

DO - 10.15252/emmm.201505431

M3 - Article

C2 - 26174485

SN - 1757-4684

VL - 7

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 9

ER -